MIRA Pharma Phase 1 SAD of Ketamir-2 safe, well tolerated; positive PK

MIRA PHARMACEUTICALS, INC.

Phase 1 SAD study in 32 healthy volunteers (50-600 mg doses) showed no severe or serious adverse events.
Dose-proportional exposure (Cmax, AUC); median Tmax 1-2 h; half-life 2-5 h; metabolite nor-Ketamir half-life 6.5-8.5 h.
Company to initiate MAD portion of Phase 1, followed by Phase 2a trial in neuropathic pain patients.
DEA concluded Ketamir-2 is not a controlled substance under the Controlled Substances Act.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.